Markers of Atrial Fibrillation
| Status: | Recruiting |
|---|---|
| Conditions: | Atrial Fibrillation, Neurology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/14/2018 |
| Start Date: | August 2011 |
| End Date: | April 2019 |
| Contact: | Glen Jickling |
| Email: | gcjickling@ucdavis.edu |
Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate
This study will evaluate whether a gene marker can improve the identification of atrial
fibrillation in patients with ischemic stroke, and evaluate whether the decision to
anticoagulate could be improved by a marker of atrial fibrillation.
fibrillation in patients with ischemic stroke, and evaluate whether the decision to
anticoagulate could be improved by a marker of atrial fibrillation.
Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify
because anticoagulation provides a 66% risk reduction in recurrent stroke. However,
opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and
therefore not detected at the time of stroke. In addition, even when AF is identified
anticoagulation may not be initiated due to perceived contraindications.
This study will (1) evaluate whether a gene marker can improve the identification of AF in
patients with ischemic stroke, and (2) evaluate decisions by health care provider and
patients to anticoagulate AF, and whether this decision could be improved by a marker of AF
at time of stroke. An AF Gene Score will be developed comprised of genes associated with
inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients
with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid
identification of stroke due to AF which may increase initiation of anticoagulation therapy.
This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty
regarding the association of delayed AF with initial stroke and delays anticoagulation.
because anticoagulation provides a 66% risk reduction in recurrent stroke. However,
opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and
therefore not detected at the time of stroke. In addition, even when AF is identified
anticoagulation may not be initiated due to perceived contraindications.
This study will (1) evaluate whether a gene marker can improve the identification of AF in
patients with ischemic stroke, and (2) evaluate decisions by health care provider and
patients to anticoagulate AF, and whether this decision could be improved by a marker of AF
at time of stroke. An AF Gene Score will be developed comprised of genes associated with
inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients
with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid
identification of stroke due to AF which may increase initiation of anticoagulation therapy.
This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty
regarding the association of delayed AF with initial stroke and delays anticoagulation.
Inclusion Criteria:
- Ischemic stroke within 72 hours of onset
- Complete evaluation to determine cause of stroke
- Informed Consent
Exclusion Criteria:
- Active Infection
- Lymphoma / Leukemia / Blood dyscrasia
- Hemorrhagic stroke
- Immunosuppressive therapy
- Illicit drug use
- Blood transfusion +/- 1 month
- Major surgery/trauma in last 6mts
We found this trial at
1
site
University of California-Davis As we begin our second century, UC Davis is poised to become...
Click here to add this to my saved trials
